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OBJECTIVES The purpose of this study was to evaluate the predictive accuracy of positron emission
tomography (PET) blood flow–F-18 fluorodeoxyglucose (FDG) imaging in coronary artery
disease (CAD) patients with diabetes mellitus (DM).
BACKGROUND Positron emission tomography accurately predicts the postrevascularization improvement in
left ventricular dysfunction in unselected patients with CAD. In diabetic patients, however,
poor myocardial glucose utilization may limit the accuracy of the approach.
METHODS Forty patients (64 6 10 years old; 19 with DM 5 group I; 21 without DM 5 group II) with
reduced left ventricular ejection fraction (LVEF 5 29 6 6%) were studied with N-13
ammonia and FDG PET before coronary revascularization. Studies were performed after
intravenous injection of regular insulin (group I) or oral glucose administration (group II).
Blood flow–FDG mismatches and matches were identified by polar map analysis in the three
vascular territories of the left anterior descending, left circumflex and right coronary artery.
Wall motion and LVEF were assessed by two-dimensional echocardiography before and
158 6 123 days after revascularization.
RESULTS Of 107 vascular territories analyzed, 46 were classified as mismatch, 29 as match and 32 as
normal. The FDG image quality, assessed by F-18 myocardium to blood pool activity ratios, and
the predictive accuracy were similar in both groups; presence of a blood flow/FDG mismatch had
a sensitivity of 92% (group I) and 94% (group II) and a specificity of 85% (group I) and 79%
(group II) for an improvement in regional left ventricular function. A postrevascularization
improvement in global left ventricular function was related to the extent of blood flow/FDG
mismatch; LVEF increased from 30 6 7% to 35 6 7% (p 5 0.017) in patients with one mismatch
and from 27 6 4% to 41 6 7% (p , 0.001) in those with two mismatches.
CONCLUSIONS The predictive accuracy of blood flow/FDG imaging is maintained in patients with DM
when a clinically acceptable study protocol, which guarantees good FDG image quality, is
used. The extent of a blood flow/metabolism mismatch is correlated with the magnitude of
the postrevascularization improvement in global left ventricular function. (J Am Coll Cardiol
1999;33:1328–37) © 1999 by the American College of Cardiology
More than a decade ago Tillisch et al. (1) demonstrated that
a postrevascularization improvement in regional and global
left ventricular function could be predicted from patterns of
blood flow and glucose utilization as evaluated with positron
emission tomography (PET). Subsequent studies confirmed
that maintained glucose metabolism in hypoperfused, dys-
functional myocardium, referred to as blood flow–
metabolism mismatch, predicts functional recovery with an
accuracy ranging from 72% to 95% (1–6). Flow–metabolism
patterns therefore yield valuable diagnostic and prognostic
information in patients with coronary artery disease (7–9).
Myocardial utilization of exogenous glucose can be visu-
alized with F-18 fluorodeoxyglucose (FDG) and PET. The
diagnostic quality of FDG images, and hence the accuracy
From the Department of Molecular and Medical Pharmacology, Division of
Nuclear Medicine, UCLA School of Medicine; and Laboratory of Structural Biology
and Molecular Medicine, University of California, Los Angeles, California. The
Laboratory of Structural Biology and Molecular Medicine is operated for the U.S.
Department of Energy by the University of California under Contract #DE-FC03-
87ER60615. This work was supported in part by the Director of the Office of Energy
Research, Office of Health and Environmental Research, Washington, D.C., by
Research Grant and #HL 33177, National Institutes of Health, Bethesda, Maryland
and by an Investigative Group Award by the Greater Los Angeles Affiliate of the
American Heart Association, Los Angeles, California. Dr. Scho¨der’s work was
supported in part by Grants from the German Academic Exchange Service and the
German Academy of Natural Scientists Leopoldina.
Manuscript received January 12, 1998; revised manuscript received November 13,
1998, accepted December 24, 1998.
Journal of the American College of Cardiology Vol. 33, No. 5, 1999
© 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00
Published by Elsevier Science Inc. PII S0735-1097(99)00010-8
of blood flow–metabolism images for predicting the pos-
trevascularization outcome in left ventricular contractile
function depends on myocardial glucose uptake. Typically,
glucose is administered orally to stimulate insulin secretion
and, thus, to enhance myocardial glucose utilization and
FDG uptake. In patients with diabetes mellitus, however,
reduced myocardial glucose utilization results in poor FDG
uptake and image quality (10,11), which limits the diagnos-
tic accuracy of PET blood flow–metabolism images. Be-
cause of the high prevalence of coronary artery disease in
diabetic patients (12–14), they represent a substantial frac-
tion of patients in whom identification of viable myocar-
dium is important. Yet, the accuracy of PET blood flow–
metabolism imaging has not been determined systematically
in this patient group.
To improve the FDG image quality Hicks et al. (15) and
Knuuti et al. (16) recommended the hyperinsulinemic–
euglycemic clamp. However, the approach is labor intensive
and time-consuming and therefore clinically impractical.
The aims of the present study were therefore a) to evaluate
in patients with diabetes mellitus the clinical and diagnostic
utility of a more practical blood flow–metabolism imaging
protocol and b) to assess its predictive accuracy on the
postrevascularization recovery of regional and global left
ventricular function.
METHODS
Study population. The study population consisted of 40
consecutive patients with coronary artery disease. All pa-
tients underwent coronary artery bypass surgery or percuta-
neous transluminal coronary angioplasty. Regional and
global left ventricular function was assessed with two-
dimensional echocardiography before and after revascular-
ization. Patients were grouped according to presence or
absence of diabetes mellitus (Table 1). Group I consisted of
19 patients with previously diagnosed diabetes mellitus; the
diagnosis of diabetes mellitus was based on a fasting plasma
glucose level of .120 mg/dl. There were 14 male and 5
female subjects with a mean age of 64 6 11 years. Seventeen
patients had non–insulin-dependent (NIDDM) and two
patients insulin-dependent diabetes mellitus (IDDM, pa-
tients 12 and 19 in Table 1). Group II consisted of 21
patients (19 male, 2 female, mean age 65 6 9 years) with
coronary artery disease but without diabetes (fasting plasma
glucose concentrations less than 120 mg/dl).
The two groups were similar in age, gender, New York
Heart Association (NYHA) heart failure symptoms, coro-
nary arteriographic findings and left ventricular ejection
fraction (LVEF; Table 1). Fourteen patients in group I and
14 in group II had prior myocardial infarctions, coronary
artery bypass surgery or percutaneous transluminal coronary
angioplasty. Heart failure symptoms (NYHA) class III or
IV were present in 14 patients in group I and 16 patients in
group II. Further, one patient in each group suffered from
chronic renal failure.
Coronary angiography was performed within three
months, and two-dimensional echocardiography and PET
imaging 31 6 53 days before revascularization. All group I
patients had three-vessel disease; in group II, three patients
had double-vessel and 18 patients had triple-vessel disease.
Positron emission tomography. All patients fasted over-
night. Myocardial blood flow and exogenous glucose utili-
zation were determined noninvasively with N-13 ammonia,
FDG and a Siemens/CTI ECAT 931/8 or ECAT EXAT
HR plus whole body positron emission tomograph (17–19).
The images were reconstructed using a Shepp filter with a
cutoff frequency of 0.3 cycles per pixel, resulting in an
effective in-plane resolution of 10.5 mm at full width at half
maximum (17,20). Both patient groups underwent the same
study protocol; initial acquisition of transmission images for
20 min was followed by static perfusion imaging for 20 min
after intravenous N-13 ammonia (15 mCi) and by static
glucose metabolism imaging for 20 min, which began 35 to
60 min after intravenous FDG (10 mCi).
Patient preparation for FDG imaging. Plasma glucose
was measured immediately before the 20-min transmission
scan followed by immediate oral glucose and/or intravenous
insulin administration. Baseline plasma glucose levels aver-
aged 86 6 10 mg/dl (range 65 to 102 mg/dl) in nondiabetic
patients. These patients received an average of 55 g (range
40 to 100 g) of glucose orally to stimulate insulin secretion,
thereby enhancing myocardial glucose and FDG uptake. In
the diabetic patients, plasma glucose averaged 200 6 87
mg/dl (range 100 to 410 mg/dl; p 5 0.0001 vs. nondiabet-
ics). According to our clinical study protocol, diabetic
patients were subdivided into two groups—patients with
plasma glucose .150 mg/dl and those with plasma glucose
#150 mg/dl.
In 15 diabetic patients, plasma glucose was .150 mg/dl.
Therefore, only (regular) insulin was administered intrave-
nously to enhance the uptake of FDG into myocardium and
to accelerate its clearance from blood. Initially 4 IU insulin
was injected. Glucose measurements and insulin injections
were then repeated every 20 min until plasma glucose levels
declined to #140 mg/dl or by at least 20%; only at that time
was the FDG image acquisition started. These patients
received a mean of 6 6 6 IU insulin intravenously.
In four diabetic patients baseline plasma glucose was
#150 mg/dl (mean 125, range 100 to 140 mg/dl). There-
fore, an initial injection of 2 to 4 IU of intravenous insulin
Abbreviations and Acronyms
FDG 5 F-18 fluorodeoxyglucose
IDDM 5 insulin-dependent diabetes
LVEF 5 left ventricular ejection fraction
NIDDM 5 non–insulin-dependent diabetes
NYHA 5 New York Heart Association
PET 5 positron emission tomography
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was combined with the oral administration of 25 g glucose
to avoid hypoglycemia.
Positron emission tomography image analysis. The
transaxially acquired image sets were reoriented into six
short axis cuts which were then assembled into polar maps
of the distribution of N-13 ammonia and of FDG in the left
ventricular myocardium (17,21). Vascular territories were
classified as showing normal or reduced perfusion based on
the N-13 ammonia polar maps; N-13 activity concentra-
tions within 2 SDs of the mean of a database of normal
measurements were considered normal (17). Extent and




























1 M 61 mm 2 1 mm 2 0 m 2 2 35 45
2 M 54 mm 3 0 n 0 0 n 1.5 1.5 30 40
3 M 87 n 2 2 mm 2 0 mm 3 2 30 45
4 M 56 mm 2 0 n 2 0 mm 2 1 25 45
5 M 57 m 2 1.5 n 1 1.5 mm 2 1.5 37 38
6 M 58 mm 1.5 0 mm 1.5 0 m 1.5 1.5 25 40
7 M 68 n 2 1.5 n 1 1.5 n 1 1.5 35 38
8 F 67 n 0 0 n 0 0 mm 3 2 43 45
9 M 69 mm 3 0 mm 1 0 mm 3 2 30 50
10 M 72 mm 1 0 m 2 1 mm 2 1 25 50
11 M 61 m 2.5 2.5 n 2.5 2.5 n 2 2 35 35
12 F 74 mm 3 1 m 2 2 n 1 1 25 35
13 M 66 n 1 3 mm 1 0 mm 2.5 0.5 25 35
14 F 75 n 1 1 n 2 0 m 2 1 35 40
15 F 50 n 1 2 m 1 2 m 2 2 30 20
16 M 57 mm 2 0 mm 2 0 mm 2 1.5 20 35
17 M 56 m 2 2 mm 2 0 m 2 2 23 33
18 M 78 mm 2 1 m 2 2 m 2 3 25 25
19 F 45 mm 2 0 n 0 0 n 1 0 24 38
Mean 64 1.8 1.0 1.42 0.66 2.0 1.53 29.3 38.5
SD 11 0.8 1.0 0.79 0.93 0.6 0.68 6.0 7.6
Group II
1 M 66 mm 2 0 n 0 0 mm 2 1 30 53
2 M 77 mm 2 0 n 0 0 n* 1.5 1.5 30 45
3 M 55 m 1.5 1.5 n 1.5 1.5 mm 3 1.5 35 35
4 M 78 m 1.5 1.5 n 1.5 1.5 m 1.5 1.5 33 30
5 M 78 n 3 1.5 n 1.5 1.5 m 1.5 1.5 28 32
6 M 53 m 2 2 m* 2 2 m* 2 2 22 26
7 M 62 m 3 2.5 m 1 2 m 1.5 3 35 35
8 M 76 n 1 1.5 n 0 1.5 mm 1.5 1.5 40 30
9 M 62 n 2 1 n 0 1 n 1 1.5 35 47
10 F 65 m* 2 2 mm* 2 2 mm 2 0 23 30
11 M 65 m 2 2 m 2 2 m 1 2 23 20
12 M 50 n 2 3 mm 2 3 mm 2 3 23 35
13 M 50 m 1.5 0 n 1.5 0 m 1.5 1.5 35 45
14 M 62 n 1.5 3 mm 1.5 1.5 mm 3 1.5 33 35
15 M 55 n 2 1.5 n 2 1.5 m 2 2.5 25 25
16 M 71 mm 2 1 mm 2 1 mm 2 0 40 54
17 M 64 mm 2.5 1 n 2 2 m 2 2 25 30
18 M 72 mm 2 1 n 1 1 mm 1.5 0 30 44
19 F 67 n 2 2 mm 3 1 n 1 0 31 35
20 M 68 mm 2 1 n 2 1 mm 2 1 25 30
21 M 71 mm 2 1 mm 2 1 m 2 3 20 33
Mean 65 2.0 1.4 1.5 1.3 1.8 1.5 29.6 35.7
SD 9 0.5 0.86 0.84 0.75 0.5 0.95 5.9 9.1
*Excluded from analysis because of graft occlusion or because territory was not revascularized. EF 5 left ventricular ejection fraction; F 5 female; LAD 5 left anterior descending
artery; LCX 5 left circumflex coronary artery; M 5 male; m 5 match; mm 5 mismatch; n 5 normal; PET 5 positron emission tomography; RCA 5 right coronary artery;
RWM 5 regional wall motion.
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severity of perfusion defects were determined for each of the
three coronary vascular territories and the entire left ven-
tricular myocardium; extent reflects the hypoperfused area
as the fraction of pixels of a vascular territory or the entire
left ventricle, and severity reflects the average percent
reduction of the relative N-13 ammonia uptake less than 2
SDs below the normal mean (17).
The FDG uptake was normalized to myocardium with
normal blood flow and a difference polar map (N-13
ammonia–FDG) created for comparison with a normal
database (17). Perfusion defects were then subclassified into
those with blood flow–metabolism mismatches and
matches. Mismatch was defined as relative difference be-
tween the relative F-18 and N-13 concentrations greater
than 2 SDs above the normal mean and match as a
concordant reduction of both N-13 and F-18 activity by
more than 2 SDs below the normal mean (17). A vascular
territory was considered to exhibit the match or mismatch
pattern only if more than 15% of that territory was hypoper-
fused (22).
To assess the FDG image quality, regions of interest (50
pixels each) were placed in the left ventricular cavity in the
center of the blood pool and in left ventricular segments
with normal myocardium (based on normal resting perfu-
sion assessed by N-13 ammonia) on midventricular short-
axis slices. Counts per pixel were averaged, and a myocar-
dium to blood pool activity ratio was calculated by dividing
the myocardial by the blood pool activity counts. Regions of
interest (ROIs) were not placed in the interventricular
septum or in match territories to avoid artificially elevated
(right ventricular activity spillover into the septum) or
decreased (match) myocardium to blood pool activity ratios.
The diagnostic image quality was also assessed by visual
inspection by three independent readers (C.K.H., D.H.M.,
J.C.) who were blinded to clinical data.
Two-dimensional echocardiography. Regional wall mo-
tion was evaluated with two-dimensional echocardiography
from four- and two-chamber, and apical long-axis views.
Echocardiograms were analyzed by clinical cardiologists
who were blinded to the PET data. Regional wall motion
was graded in six myocardial segments (anterior, anterolat-
eral, inferolateral, inferior, inferoseptal, anteroseptal) on a
4-point scale where 0 5 normal, 1 5 mild hypokinesis, 2 5
severe hypokinesis and 3 5 akinesis or dyskinesis. The six
myocardial segments were assigned to one of the three
vascular territories as follows: the anteroseptal and anterior
wall to the left anterior descending coronary artery, the
anterolateral and inferolateral wall to the left circumflex and
the inferior and inferoseptal wall to the right coronary
artery. Wall motion scores in each of the two segments per
vascular territory were averaged. The left ventricular ejection
fraction was determined with a standard echocardiography
package using the Simpson rule (23). Follow-up echocardi-
ography was performed 156 6 118 (range 25 to 365) days
after revascularization in group I and 160 6 130 (range 25
to 380) days after revascularization in group II (p 5 NS).
Changes by at least one grade in the motion score in a
coronary vascular territory were considered significant.
Statistical analysis. Mean values are given with SD. Mis-
match segments with functional improvement after revas-
cularization were considered as true positive and those
without improvement as false positive. Likewise, segments
with match and without functional improvement were
considered as true negative and those with functional
improvement as false negative. Sensitivity, specificity, pre-
dictive values and accuracy were calculated (24). Dysfunc-
tional segments with normal blood flow were treated sepa-
rately, as their functional outcome may be related to the
underlying pathophysiologic mechanism (see Discussion).
Comparison of continuous data within one group was
performed using Student t test for paired data, comparisons
between groups by unpaired t test or, for comparisons
between more than two groups, by analysis of variance
(ANOVA) followed by Bonferroni’s modified t test. Non-
parametric testing (Fisher exact test) was used for compar-
ison of sensitivity, specificity, accuracy and number of
mismatches, matches and normal territories between
groups. Nonparametric testing (chi-square, runs test) was
also employed a) to evaluate whether presence of a certain
blood flow–metabolism pattern in one coronary territory
was independent of blood flow and metabolism in the other
territories in a given patient and b) to assess potential trends
and correlations of postrevascularization changes in wall
motion between the three coronary vascular territories in
each patient. Regression analysis employed nonweighted
least-square fitting. A p value of ,0.05 was considered
significant.
RESULTS
Effects of glucose load and insulin administration.
Plasma glucose levels declined in group I patients to 136 6
38 mg/dl (range 75 to 200) after insulin injection (p , 0.05
vs. baseline) and were similar to those in group II after oral
glucose administration (139 6 20 mg/dl) (Fig. 1).
The time from oral glucose administration (in nondia-
betic patients) or first insulin injection (in diabetic patients)
to the beginning of the FDG PET imaging was similar for
both groups (121 6 32 min in group I vs. 111 6 21 min in
group II, p 5 0.22).
F-18 Fluorodeoxyglucose PET image quality. The diag-
nostic quality of the FDG images was considered sufficient
in all studies by the three independent readers. This is also
reflected by comparable F-18 myocardium to blood pool
activity ratios for both patient groups (2.70 6 0.74 in group
I and 3.09 6 0.79 in group II, p 5 NS). The myocardium
to blood pool ratios in the two patients with IDDM were
2.9 and 3.3 respectively, and thus were similar to those
observed in NIDDM patients.
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Coronary revascularization and regional wall motion
analysis. In group I, all patients underwent coronary artery
bypass surgery (CABG). The mean number of grafts per
patient was 4.2 6 0.9. One patient had mitral valve
replacement, another one aneurysmectomy in addition to
bypass surgery. In group II, 18 patients underwent coronary
artery bypass surgery; the mean number of grafts per patient
was 4.1 6 0.9. Two patients had aneurysmectomy or
endoaneurysmorrhaphy in addition to bypass surgery. In
one of these patients (Table 1, number 10), the postsurgical
coronary angiogram revealed occlusion of the left anterior
descending artery graft (excluded from analysis), whereas
the other graft was patent. Two patients had single-vessel
percutaneous transluminal coronary angioplasty only, and
one patient had angioplasty of the left anterior descending
artery and the left circumflex coronary artery. The time
interval between blood flow–FDG PET and coronary re-
vascularization was similar for both study groups (25 6 32
vs. 20 6 43 days, p 5 NS).
There were a total of 120 coronary vascular territories
(three per patient). Eight territories exhibited normal wall
motion and normal perfusion; these were excluded from
analysis. Of the remaining 112 territories with abnormal
wall motion, one hypokinetic territory was excluded because
of postoperative graft occlusion (see above) and four other
territories were excluded because they had not been revas-
cularized.
The remaining 107 territories, that is, 53 in group I and
54 in group II, were analyzed (Fig. 2). In group I, 9
territories showed akinesis, 32 severe hypokinesis and 12
mild hypokinesis. In group II, 6 territories showed akinesis,
42 severe hypokinesis and 6 mild hypokinesis (Table 1).
Seventy-five of the 107 dysfunctional territories had abnor-
mal resting perfusion on polar map analysis; the extent of
perfusion defects in these 75 territories averaged 57 6 19%
per coronary artery territory in group I and 61 6 25% in
group II (p 5 NS). The extent of the preoperative perfusion
defects was similar for territories with match or mismatch
pattern (51 6 26% vs. 51 6 22%; p 5 NS) and tended to
correlate with the severity of wall motion abnormalities (r 5
0.3, p 5 0.04). Neither extent nor severity of perfusion
defects correlated with the magnitude of a postoperative
improvement in regional wall motion (r 5 0.04, p 5 NS).
The presence of a certain pattern of blood flow and
metabolism in a given vascular territory was independent of
blood flow–metabolism patterns in the other two vascular
territories of the same patient (p 5 0.24, NS).
Predictive accuracy of myocardial blood flow–
metabolism patterns. POSTSURGICAL CHANGES IN WALL
MOTION ABNORMALITIES. A blood flow–metabolism mis-
match was present in 46 territories (in 27 patients), whereas
29 territories (in 19 patients) exhibited a match (Fig. 2).
Forty mismatch territories (in 25 patients) showed improve-
ment in regional wall motion after revascularization,
whereas six (in five patients) did not. Thus, the overall
sensitivity and specificity of the mismatch pattern for an
improvement in regional wall motion were 93% and 81%,
respectively. Positive and negative predictive values were
87% and 90%, and the overall predictive accuracy of the test
Figure 1. Plasma glucose concentrations in group I diabetic
patients and group II nondiabetic patients at baseline (open bars)
and after intravenous insulin injection (group I) or oral glucose
load (group II), respectively (shaded bars). Data are mean 6 1 SD.
Figure 2. Representation of coronary vascular territories according to their positron emission tomography blood flow–metabolism imaging
patterns and changes in regional wall motion (WM) after coronary revascularization.
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was 88%. The mean extent of a mismatch in a given vascular
territory was similar in both groups (45 6 22% in group I vs.
58 6 31% in group II; p 5 NS). No trend or correlation was
found regarding postrevascularization changes in wall mo-
tion between the three coronary vascular territories per
patient, that is, changes in wall motion in one territory did
not predict similar changes in the other two coronary
territories in a given patient (p 5 0.27 and 0.67, respective-
ly).
In the group I (diabetic) patients, there were 25 territories
(in 15 patients) with flow–metabolism mismatches and 13
(in 10 patients) with matches (Fig. 3A). Postoperatively,
regional wall motion improved in 23 territories (in 14
patients) with mismatch but only in two territories (in two
patients) with match. Sensitivity and specificity of the
flow–metabolism mismatch pattern for predicting the pos-
trevascularization outcome in myocardial dysfunction were
92% and 85%, respectively. Positive and negative predictive
values of the mismatch pattern were 92% and 85%, respec-
tively, with an overall predictive accuracy of 89%.
In the group II (nondiabetic) patients, 37 territories were
analyzed: 21 territories (in 11 patients) with a blood
flow–metabolism mismatch and 16 territories (in 10 pa-
tients) with a match pattern. Regional wall motion im-
proved following revascularization in 18 territories, 17 of
them with a mismatch pattern (in 11 patients) and one with
match (Fig. 3B). Wall motion remained unchanged or
deteriorated in 19 territories. Four had a blood flow–
metabolism mismatch, and 15 had a match. Two patients in
this group (numbers 13 and 19) underwent aneurysmectomy
or endoaneurysmorrhaphy in addition to coronary revascu-
larization. Postsurgically, the respective mismatch territories
demonstrated complete or almost complete recovery of wall
motion. Sensitivity and specificity of the mismatch pattern
for an improvement in regional wall motion were 94% and
79%, respectively. Positive and negative predictive values
were 81% and 94% with an overall predictive accuracy of
86%.
Sensitivity, specificity, predictive values and accuracy of
the mismatch pattern for functional improvement after
coronary revascularization did not differ between group I
and group II patients.
CHANGES IN GLOBAL LEFT VENTRICULAR FUNCTION. For
the whole patient population the left ventricular ejection
fraction improved significantly from 29.5 6 5.9% to 37.0 6
8.4% (p , 0.01). The improvement was similar in group I
and group II patients (p , 0.01 for both; Table 1).
The amount of reversibly dysfunctional myocardium
appears critical for a postoperative improvement in global
left ventricular function. This study found a linear correla-
tion between the extent of mismatch and the postsurgical
improvement in left ventricular function (y 5 6.5x 2 0.6,
r 5 0.56, p 5 0.0017). As depicted in Figure 4, the left
ventricular ejection fraction improved in patients with one
mismatch (n 5 13) by 18% from 30.0 6 6.8% to 35.3 6
5.9% (p 5 0.017), in those with two mismatches (n 5 12)
by 51% from 27.1 6 4.4% to 40.8 6 7.3% (p 5 0.0001) and
in those with three mismatches (n 5 3) by 53% from 30 6
10% to 46 6 10% (p 5 0.012).
Dysfunctional myocardium with normal blood flow and
glucose metabolism. As shown in Figure 2, there were 32
territories (15 in group I and 17 in group II) with mild to
moderate hypokinesis (n 5 31) or akinesis (n 5 1) but
normal blood flow and glucose metabolism. After revascu-
larization, eight of these territories showed functional im-
provement; 24 demonstrated no change (n 5 21) or
worsening (n 5 3) in regional wall motion. The lack of
functional improvement was not related to the time of
Figure 3. Changes in regional wall motion after coronary revas-
cularization in group I diabetic patients (Top) and group II
nondiabetic patients (Bottom) according to their positron emis-
sion tomography blood flow–metabolism imaging patterns.
Figure 4. Improvement in global left ventricular function after
coronary revascularization and its relationship to the number of
positron emission tomography mismatch territories; open bars
indicate presurgical, shaded bars postsurgical left ventricular
ejection fraction. Data are mean 6 1 SD.
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follow-up (181 6 126 days vs. 131 6 120 days, p 5 0.24)
or any demographic parameter. Thus, blood flow–
metabolism imaging did not predict the postsurgical out-
come of hypokinetic or akinetic myocardium with normal
resting perfusion.
DISCUSSION
In the present study, the predictive accuracy of PET
myocardial blood flow–FDG imaging for an improvement
in left ventricular dysfunction after coronary revasculariza-
tion was similar in diabetic and nondiabetic patients and in
agreement with early observations in unselected patient
populations. The study demonstrates therefore that the
predictive accuracy of myocardial blood flow–FDG imaging
by PET is maintained in patients with diabetes mellitus
when an appropriate study protocol is used. F-18 Fluoro-
deoxyglucose images of good diagnostic quality can be
obtained in diabetic patients without the need for a glucose–
insulin clamp by using small intravenous doses of regular
short-acting insulin. Thus, PET imaging of blood flow and
glucose metabolism can be used to identify reversibly
dysfunctional myocardium in patients with diabetes melli-
tus.
Methodological considerations. Diabetic patients charac-
teristically demonstrate FDG images of poor diagnostic
quality because of high blood pool and low myocardial
tracer activity, resulting in a high proportion of uninterpret-
able studies (10,25).
EUGLYCEMIC HYPERINSULINEMIC CLAMP. Previously, the
euglycemic–hyperinsulinemic clamp technique has been
proposed for improving the image quality of cardiac FDG
studies. The clamp technique aims at achieving stable
plasma glucose concentrations, a prerequisite for quantita-
tive analysis of glucose utilization, but also improves myo-
cardium to blood pool F-18 activity ratios and hence the
FDG image quality (15,16). Preliminary data suggest that
with the clamp technique comparable predictive accuracies
of blood flow–FDG imaging can be achieved for diabetic
(70%) and nondiabetic patients (67%) (26). However, the
technical demands of the clamp method may preclude its
routine use in the clinical setting.
NICOTINIC ACID DERIVATIVES. Alternatively, the nicotinic
acid derivative acipimox has been used to improve myocar-
dial FDG image quality (27–29). The agent inhibits lipol-
ysis and lowers circulating free fatty acid levels, which in
turn promotes myocardial glucose uptake (29–31). In a
small number of patients, Knuuti et al. (27) compared
myocardial glucose uptake during glucose–insulin clamp
and after oral administration of acipimox. In patients with
NIDDM, acipimox and the clamp technique reduced
plasma glucose concentrations to similar levels. Image
quality and identification of regions as normal, match or
mismatch were similar with both techniques. In eight
nondiabetic patients, Bax et al. (28) compared FDG images
obtained with single photon emission computed tomogra-
phy after acipimox, after oral glucose loading and using the
clamp technique. Again, both the clamp technique and
acipimox achieved similar image quality, and both were
slightly superior to oral glucose loading. However, acipimox
is not widely available in many countries. Use of another
more widely available nicotinic acid derivative, niacin, which
lowers plasma free fatty acids and enhances myocardial
glucose uptake and metabolism, does not yield superior
image quality compared with oral glucose load or insulin
injections (32). More important, no study to date has
systematically explored whether the reported improvement
in FDG image quality with acipimox translates into a
superior predictive accuracy of FDG imaging for the im-
provement in regional and global left ventricular dysfunc-
tion.
BOLUS INSULIN INJECTION. The current study examined
the feasibility of another approach for enhancing myocardial
FDG uptake, that is, titration of plasma glucose levels with
small intravenous doses of regular, short-acting insulin
(10,11). As the results demonstrate, the approach yielded
FDG images of good diagnostic quality. Myocardium to
blood pool activity ratios in diabetic patients were similar to
those in nondiabetic patients. In addition, the time interval
from study initiation to FDG image acquisition was not
longer for diabetic than for nondiabetic patients, implying
that the approach is feasible in the clinical setting.
The concept of bolus insulin injections is not new (33).
However, no systematic comparison of image quality and
predictive accuracy of blood flow–metabolism imaging be-
tween diabetic and nondiabetic patients has been reported
previously. Hence, the current study is the first to document
that the presence of diabetes mellitus per se does not
compromise the predictive accuracy of blood flow–
metabolism mismatch patterns when an appropriate study
protocol is used, and that clinical FDG imaging can be
performed without using the rather labor-intensive glucose–
insulin clamp technique; positive and negative predictive
value and the predictive accuracy of the mismatch pattern
for a recovery of left ventricular dysfunction were similar in
diabetic and nondiabetic patients and consistent with data
previously reported in unselected patient populations (1–
6,34). The proposed protocol for clinical FDG imaging
might be of even greater importance because many centers
are now starting to employ FDG single photon emission
computed tomography imaging for the assessment of myo-
cardial viability.
STUDY POPULATION. The study population is representa-
tive of that referred consecutively to the PET clinic for the
assessment of myocardial viability. There were only two
patients with IDDM; 17 patients had NIDDM. This
distribution of diabetic patients is consistent with the
prevalence of diabetes mellitus in the United States. Insulin-
dependent diabetes occurs in approximately 10% of the
diabetic population; NIDDM is present in the remaining
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90% (35,36). The small number of patients with IDDM
precludes a meaningful statistical comparison between both
types of diabetes. However, the present data suggest that the
proposed standardization protocol is equally effective in
patients with NIDDM and with IDDM.
Predictive accuracy of blood flow–metabolism imaging.
The predictive accuracy of the blood flow–metabolism
mismatch pattern in the current study compares well with
that in previous reports (1–6,34). Nevertheless, several
reasons may account for false positive studies, that is, a lack
of functional improvement in segments with mismatch.
First, ventricular function after bypass surgery recovers only
slowly, sometimes over a period of several months (37–39).
Thus, measures of outcome are critically related to the time
of follow-up. However, the lack of functional recovery in
the present study was not related to the time of echocar-
diographic follow-up, which was similar for patients with
and without functional improvement (196 6 134 days vs.
122 6 57 days, p 5 0.15). Echocardiography was performed
in two patients on day 25 after revascularization; both
demonstrated a significant improvement at that time. Also,
in 14 of 15 patients with more than one mismatch, most
territories showed functional improvement. Differences in
follow-up time periods are therefore unlikely to account for
the lack of functional recovery in some mismatch segments.
However, possible differences in the magnitude and
extent of structural alterations between territories with and
without improvement in contractile function cannot be
excluded with certainty. For instance, histomorphologic
studies have shown that the extent of fibrotic tissue in a
given myocardial segment is directly related to the magni-
tude of recovery of contractile function (40,41). Other
factors such as the fraction of abnormal myocytes also affect
magnitude and possible time course of the functional
recovery (40,42,43).
Dysfunctional myocardium with normal perfusion and
glucose metabolism. Thirty-two territories exhibited nor-
mal perfusion and FDG utilization despite abnormal re-
gional wall motion; mild to moderate hypokinesis was noted
in 31 territories and akinesis in one territory. Only eight
(25%) territories had improved wall motion after revascu-
larization. These findings could reflect either ventricular
remodeling or repetitively stunned myocardium. Ventricular
remodeling is a dynamic process that is initiated by a loss of
contractile tissue due to myocardial infarction or chronic
coronary artery disease. Subsequently, the excessive work-
load and compensatory hypertrophy of the residual viable
tissue can lead to structural and functional alterations of the
remote myocardium (44,45). It is possible that in the
current patient population with end-stage coronary artery
disease and severely impaired left ventricular function a
number of segments with normal blood flow and metabo-
lism did in fact represent remodeled myocardium. It is
currently unknown whether such remodeled myocardium
can undergo structural and functional improvements after
revascularization. Alternatively, dysfunctional myocardium
with normal blood flow at rest might also result from
repeated stunning (34,46–48). In this scenario, coronary
revascularization prevents further ischemic episodes and
allows recovery of contractile function. Demonstration of
stunning as a possible explanation would have required an
additional stress perfusion study, which was not performed
in the current patient population. Nevertheless, because of
the severity of coronary artery disease in our study popula-
tion, stunning is likely to account at least in some segments
with normal and perfusion metabolism at rest for the
reversible dysfunction. The current findings imply that PET
images of blood flow and metabolism acquired only at rest
do not elucidate mechanisms of contractile dysfunction and
do not discriminate fully between reversible and irreversible
dysfunction in normally perfused myocardium.
Study limitations. The present study has some limitations.
It was performed retrospectively, and only those patients
who eventually underwent coronary revascularization were
included. However, several studies have shown that a
significant percentage of patients with viable myocardium
do not undergo coronary revascularization (7–9,49,50). This
is because the presence of viable myocardium is only one of
several criteria that determine the therapeutic approach.
Second, the majority of the group I patients in the current
study had NIDDM. Further evaluation of the proposed
standardization approach seems warranted in those with
IDDM.
Third, potential misalignments between PET and echo-
cardiographic images cannot be excluded entirely, yet data
for the overall accuracy of the test are in concordance with
previous reports. We chose rather large myocardial regions
of interest, that is, the three coronary vascular territories,
which would diminish the occurrence of major misalign-
ments between PET and echocardiography data.
Last, PET and echocardiography were performed within
4 weeks of each other. Nevertheless, it is reasonable to
expect that the PET data do reflect myocardial blood flow
and glucose utilization also at the time of echocardiography,
because relevant changes are unlikely to occur within 4
weeks in patients with chronic coronary artery disease.
Specifically, none of the patients experienced a change in his
clinical status between the two studies. In contrast, the time
between PET and coronary revascularization varied between
one day and seven months and subsequent ischemic events
might have altered the PET results. Yet, the majority of
patients underwent bypass surgery within 1 month’s time,
and three of four patients undergoing revascularization
more than 120 days after PET did in fact show an
improvement in regional and global left ventricular func-
tion.
Clinical implications. Our results indicate that blood
flow–metabolism imaging with PET accurately predicts the
outcome of myocardial dysfunction after coronary revascu-
larization in patients with diabetes mellitus. Good FDG
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image quality can be achieved using a clinically feasible and
practical protocol with intravenous administration of small
doses of regular insulin titrated against plasma glucose
levels. Using this approach, the predictive accuracy of blood
flow–metabolism patterns for the postrevascularization out-
come of regional wall motion abnormalities is preserved.
Further, the extent of a blood flow–metabolism mismatch is
directly related to the magnitude of postsurgical improve-
ment in global left ventricular function.
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